X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The new company will focus on developing innovative extended bacteriophage therapies to target antimicrobial resistance including, PhagoDAIR (anti S. aureus bacteriophage), world’s first study of phage therapy, for patients with knee or hip prosthetic joint infections.
Lead Product(s): Anti Staphylococcus aureus Bacteriophage
Therapeutic Area: Infections and Infectious Diseases Product Name: PhagoDAIR
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Phaxiam Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 26, 2023
Details:
Strategic combination will accelerate development of extended phage therapies for antimicrobial resistance including Anti-Staphylococcus aureus Bacteriophages, in particular via the phase II PhagoDAIR study conducted by PHERECYDES.
Lead Product(s): Anti-Staphylococcus Aureus Bacteriophage
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Pherecydes Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 15, 2023
Details:
In multiple clinical trials, Graspa (erythrocytes encapsulating L-asparaginase) showed promising results for patients, in hypersensitive acute lymphoblastic leukemia (ALL) to pegylated asparaginase therapy.
Lead Product(s): Erythrocytes Encapsulating L-asparaginase
Therapeutic Area: Oncology Product Name: Graspa
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
The deal includes an exclusive long-term supply agreement for Catalent to support Erytech’s lead product candidate eryaspase (GRASPA®), a red blood cell-derived product, which is currently in late-stage development for the treatment of acute lymphoblastic leukemia.
Lead Product(s): Eryaspase
Therapeutic Area: Oncology Product Name: Graspa
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: $44.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 25, 2022
Details:
Eryaspase (GRASPA®), an L-asparaginase encapsulated inside donor-derived red blood cells, demonstrated sustained asparaginase enzyme activity above the threshold of >100 U/L at trough levels 14 days after first infusion in 92.5% of patients.
Lead Product(s): L-asparaginase
Therapeutic Area: Oncology Product Name: Eryaspase
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
ERYCAPS, encapsulate active drug substances inside red blood cells using reversible hypotonic and hypertonic osmotic stress, uses transfusion-grade red blood cells taken from blood donors with a specific blood type, compatible with the blood type of patient to be treated.
Lead Product(s): RBC-loaded Enzyme
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
US patent application for Enzyme replacement therapy cover arginine deiminase encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease.
Lead Product(s): Red Blood Cell-encapsulated Arginine Deiminase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
Results from the NOPHO-sponsored Phase 2 clinical trial demonstrated that eryaspase in combination with chemotherapy, administered every two weeks, provides a sustained asparaginase enzyme activity level, and is generally well tolerated with few hypersentivity reactions.
Lead Product(s): Peg L asparaginase
Therapeutic Area: Oncology Product Name: Eryaspase
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.
Lead Product(s): L-asparaginase,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: Eryaspase
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Oral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase as a treatment option for ALL.
Lead Product(s): Peg L asparaginase
Therapeutic Area: Oncology Product Name: Eryaspase
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
